Pulmonary Arterial Hypertension: Epidemiology Forecast to 2034

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder of unknown cause, characterized by vascular proliferation and remodelling of the small pulmonary arteries. A significant number of risk factors and pathophysiological conditions are suspected to play roles in disease progression (Humbert et al., 2004, 2010; Simonneau et al., 2004; Bonnet et al., 2017). In PAH, blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs and can lead to right ventricular overload and intense right heart failure. This results in progressively increasing pulmonary vascular resistance, leading to an increase in pulmonary arterial pressure (Pugh and Hemnes, 2010; Omura et al., 2023; Mayo Clinic, 2025). The heart muscles work harder to pump blood through the lungs, eventually causing the heart muscles to become weak and fail (Mayo Clinic, 2025). PAH represents Group 1 within the World Health Organization (WHO) clinical classification for pulmonary hypertension. PAH can be idiopathic, heritable, or associated with different conditions such as connective tissue disease (CTD), congenital heart disease (CHD), human immunodeficiency virus (HIV) infection, and exposure to toxins or drugs (Simonneau et al., 2009). PAH occurs twice as frequently in women as in men (Humbert et al., 2006; Frost et al., 2011; Escribano-Subias et al., 2012; Ling et al., 2012; Farber et al., 2015; Kasahara et al., 2015; Hoeper, Huscher and Pittrow, 2016; Leber, Beaudet and Muller, 2021). Due to its unclear multifactorial mechanisms, and despite many treatment advancements over the past few decades, the long‐term prognosis of patients with PAH remains poor (Galiè et al., 2015; Bonnet et al., 2017; Omura et al., 2023).

In the 7MM, diagnosed incident cases of PAH are expected to decrease from 14,189 cases in 2024 to 14,154 cases in 2034, at a negative annual growth rate (AGR) of 0.02%. In 2034, the US will have the highest number of diagnosed incident cases of PAH in the 7MM, with 5,484 cases, whereas the UK will have the fewest diagnosed incident cases of PAH with 661 cases. The analyst epidemiologists attribute the decline in the diagnosed incident cases of PAH to changes in the population dynamics, as well as the incidence rates in each market over the forecast period.

In the 7MM, diagnosed prevalent cases of PAH are expected to decrease from 76,645 cases in 2024 to 76,035 cases in 2034, at a negative AGR of 0.08%. In 2034, the US will have the highest number of diagnosed prevalent cases of PAH in the 7MM, with 29,591 cases, whereas the UK will have the fewest diagnosed prevalent cases of PAH with 3,773 cases. The analyst epidemiologists attribute the change in the diagnosed prevalent cases of PAH to changes in population dynamics in each market over the forecast period.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for PAH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed incident cases of PAH segmented by sex and age (all ages). It also provides a forecast for diagnosed prevalent cases of PAH segmented by sex, age (all ages), severity based on New York Heart Association (NYHA) functional classes (NYHA functional classes I and II, NYHA functional class III, and NYHA functional class IV), and comorbidities (CTD, scleroderma, diabetes, chronic obstructive pulmonary disease [COPD], portal hypertension [PH], and CHD) in these markets. This epidemiology forecast for PAH is supported by data obtained from peer-reviewed articles and registry-based studies. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of PAH across these markets.

Reasons to Buy

The Pulmonary arterial hypertension (PAH) epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global PAH market.
• Quantify patient populations in the global PAH market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PAH therapeutics in each of the markets covered.